2-bromoethoxy-hyperoside for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
2-bromoethoxy-hyperoside may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed 2-bromoethoxy-hyperoside in detail.
, Phytochemical and antiviral investigation of Cynanchum acutum L. extract and derived semi-synthetic analogs targeting SARS-CoV-2 main protease, Future Journal of Pharmaceutical Sciences, doi:10.1186/s43094-025-00907-2
Abstract Background The genus Cynanchum , family Apocynaceae is a group of climbing vines that have long been in folk medicine used as antitussives, analgesics, anticonvulsants, expectorants, diuretics, antifebriles, and tonics. Results Cynanchum acutum crude extract was investigated to determine its chemical composition through LC-ESI-TOF-MS/MS technique, where 46 hits were observed. Among these compounds, quercetin-3- O - β -galactoside was previously reported within the plant as a major component. This compound was isolated and purified using different chromatographic techniques, and its concentration was estimated using high-performance thin-layer chromatography (HPTLC). Two semi-synthetic derivatives were synthesized from this compound, namely 7-benzyl- and 7-bromoethyl quercetin-3- O - β -galactosides. Both analogs, which are more hydrophobic, were developed as an attempt to improve the physiochemical properties and, in turn, the pharmacokinetics of the parent compound. Our study also includes the determination of antiviral activity against COVID-19 of Cynanchum acutum crude extract along with quercetin-3- O - β -galactoside in addition to the two semi-synthesized derivatives. The antiviral assay revealed that the synthetic benzyl derivative of quercetin-3- O - β -galactoside demonstrated promising activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The potential molecular aspects of the parent and semi-synthetic analogs were highlighted through molecular modeling simulation of docking the compounds at the viral main protease (Mpro) binding pocket. In silico findings demonstrated significant affinity and residue-wise binding interactions in relation to the co-crystallized small molecule Mpro inhibitor. Conclusion Collectively, our study adds to the current knowledge of SARS-CoV-2 pharmacotherapy by introducing drug-like small molecules with potential activity profiles. Graphical abstract